Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyMass General Brigham HAE Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Hereditary Angioedema Agents Coverage Criteria

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Kalbitor and other hereditary angioedema agents under the MassHealth medical benefit, including acute treatment, prophylaxis, continuation therapy, dosing, documentation, and authorization duration.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyHereditary Angioedema Agents Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdded step-through requirement
    Effective DateNovember 16, 2026
    Last ReviewOct 14, 2026
    Next Review DateN/A
    Key ActionBefore Kalbitor authorization, document an inadequate response or adverse reaction to one of Berinert or icatibant, or a contraindication to both.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added step-through requirements for Kalbitor involving Berinert or icatibant.

    Prior authorizationUtilization management requirement
    240 units/28 daysMaximum Kalbitor dosing limit
    >2 attacks/30 daysRequired HAE attack frequency
    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Acute-treatment approval duration
    6 monthsProphylaxis approval duration

    Medical Necessity and Authorization Criteria

    New-to-plan transition

    Authorization may be granted when the following criterion is met:

    New-to-plan transition: The member is new to the plan and is currently receiving treatment with the requested medication.

    The requested product must not be obtained as samples or through a manufacturer's patient assistance program.

    Berinert acute attack treatment

    Authorization may be granted when ALL of the following criteria are met:

    • Diagnosis of hereditary angioedema for acute attack treatment.
    • Specialist involvement: The prescriber is an allergist or immunologist, or consultation notes from an allergist or immunologist regarding the diagnosis are provided.
    • Dosing: Appropriate dosing.Maximum 1000 units per dose and over 28 days
    • Attack frequency: History of more than 2 HAE attacks per 30 days.>2 HAE attacks per 30 days

    Kalbitor acute attack treatment

    Authorization may be granted when ALL of the following criteria are met:

    • Diagnosis of hereditary angioedema for acute attack treatment.
    • Specialist involvement: The prescriber is an allergist or immunologist, or consultation notes from an allergist or immunologist regarding the diagnosis are provided.
    • Prior therapy or contraindication

      • Inadequate response or adverse reaction to one of Berinert or icatibant.One agent
      • Contraindications: Contraindication to both Berinert and icatibant.Both agents

    Ruconest acute attack treatment

    Authorization may be granted when ALL of the following criteria are met:

    • Diagnosis of hereditary angioedema for acute attack treatment.
    • Specialist involvement: The prescriber is an allergist or immunologist, or consultation notes from an allergist or immunologist regarding the diagnosis are provided.
    • Dosing: Appropriate dosing.Maximum 3360 units per 28 days
    • Attack frequency: The member has more than 2 HAE attacks per 30 days.>2 HAE attacks per 30 days

    Cinryze and Haegarda prophylaxis

    Authorization may be granted when ALL of the following criteria are met:

    HAE prophylaxis

    • Diagnosis of hereditary angioedema for prophylaxis.
    • Specialist involvement: The prescriber is an allergist or immunologist, or consultation notes from an allergist or immunologist regarding the diagnosis are provided.
    • Attack history

      • Frequent attacks: The member has more than one HAE attack per month.>1 HAE attack per month
      • Recurrent laryngeal attacks:

    Continuation therapy

    Reauthorization criteria differ by treatment type:

    • Acute-treatment continuation: For Berinert, Kalbitor, or Ruconest, documentation of the use or expiration of the previously approved product is provided.Up to 2 HAE attacks per 30 days

      The approved quantity may depend on documented previous utilization and must not exceed the quantity required to treat up to 2 HAE attacks per 30 days.

    • Prophylaxis continuation: For Cinryze or Haegarda, the member experiences a positive clinical response to the requested medication.

    For members new to the plan, the requested medication must be currently used for treatment. This pathway does not apply when the product is obtained as samples or through a manufacturer’s patient assistance program.

    Dosing and Utilization Limits

    Berinert maximum dosing
    Maximum dose per administration1,000 units
    Maximum quantity over 28 days1,000 units per 28 days
    IndicationAcute attack treatment for hereditary angioedema
    Kalbitor maximum dosing
    Maximum dose per administration240 units
    Maximum quantity over 28 days240 units per 28 days
    IndicationAcute attack treatment for hereditary angioedema

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for hereditary angioedema agents covered under the MassHealth UPPL medical benefit. Submit requests through the medical benefit authorization process.

    • Affected agents: Berinert, Cinryze, Haegarda, Kalbitor (ecallantide), and Ruconest.
    • Medical benefit phone: 833-895-2611; fax: 888-656-6671.
    Step Therapy

    Kalbitor Step-Through Requirement

    Before Kalbitor authorization, document the required step-through pathway: inadequate response or an adverse reaction to one of Berinert or icatibant, or a contraindication to both products.

    • The step-through requirement applies to Kalbitor acute-treatment requests.
    • Include the relevant treatment history, adverse reaction, or contraindication documentation.

    Hereditary Angioedema Overview

    Hereditary angioedema (HAE) is characterized by recurrent attacks of angioedema. Cinryze and Haegarda are used for prophylaxis to help prevent attacks in members who meet the applicable clinical criteria, including a history of more than 1 HAE attack per month or recurrent laryngeal attacks.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyHereditary Angioedema Agents Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAdded step-through requirement
    Effective DateNovember 16, 2026
    Last ReviewOct 14, 2026
    Next Review DateN/A
    Key ActionBefore Kalbitor authorization, document an inadequate response or adverse reaction to one of Berinert or icatibant, or a contraindication to both.
    SourceLink
    On This Page
    Medical Necessity and Authorization CriteriaDosing and Utilization LimitsAuthorization, Documentation, and Denial RisksHereditary Angioedema Overview
  1. Dosing: Appropriate dosing.Maximum 240 units per dose and over 28 days
  2. Attack frequency: History of more than 2 HAE attacks per 30 days.>2 HAE attacks per 30 days
  3. The member has a history of recurrent laryngeal attacks.
  4. Dosing: Appropriate dosing.
  5. Ruconest maximum dosing
    Maximum quantity over 28 days3,360 units per 28 days
    IndicationAcute attack treatment for hereditary angioedema
    ProductRuconest (C1 esterase inhibitor, recombinant)
    Kalbitor HAE attack frequency
    Required attack frequencyMore than 2 HAE attacks per 30 days
    Treatment typeAcute attack treatment
    ProductKalbitor (ecallantide)
    Berinert and Ruconest HAE attack frequency
    Required attack frequencyMore than 2 HAE attacks per 30 days
    Treatment typeAcute attack treatment
    ProductsBerinert and Ruconest
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation supporting the requested hereditary angioedema agent, including the diagnosis, treatment indication, prescribing specialist, and applicable clinical criteria.

    • Document hereditary angioedema and whether treatment is for acute attack treatment or prophylaxis.
    • The prescriber must be an allergist or immunologist, or consultation notes from an allergist or immunologist regarding the diagnosis must be provided.
    • For acute-treatment agents, document a history of more than 2 HAE attacks per 30 days and appropriate dosing: Berinert up to 1,000 units per 28 days; Kalbitor up to 240 units per 28 days; Ruconest up to 3,360 units per 28 days.
    • For Cinryze or Haegarda prophylaxis, document more than 1 HAE attack per month or a history of recurrent laryngeal attacks, along with appropriate dosing.
    Documentation Required

    Reauthorization Documentation

    For continuation requests, provide documentation showing use or expiration of the previously approved product. Reauthorization for Cinryze or Haegarda also requires documentation of a positive clinical response.

    • Applicable to Berinert, Kalbitor, and Ruconest: document use or expiration of the previously approved product.
    • Applicable to Cinryze and Haegarda: document positive clinical response to the requested medication.
    Denial Risk

    Samples or Patient Assistance Supply

    Requests for members new to the plan may be denied when the requested product is being obtained through samples or a manufacturer's patient assistance program.

    • Confirm the source of the member's current supply before submitting a new-to-plan request.
    Denial Risk

    Failure to Meet Kalbitor Criteria

    Kalbitor authorization may be denied when the acute-treatment criteria are not met, including failure to document hereditary angioedema, the required specialist documentation, more than 2 HAE attacks per 30 days, appropriate dosing, or the required Berinert/icatibant step-through pathway.

    • Document inadequate response or an adverse reaction to one of Berinert or icatibant, or a contraindication to both.
    • Kalbitor dosing must not exceed 240 units per 28 days.
    Denial Risk

    Unsupported Continuation Quantity

    Continuation quantities must be supported by documented prior utilization and must not exceed the amount needed to treat up to 2 HAE attacks per 30 days.

    • For Berinert, Kalbitor, and Ruconest, provide prior product use or expiration documentation.
    • Requested quantities may be reduced or denied when prior utilization does not support the request or when the quantity exceeds treatment for 2 HAE attacks per 30 days.